UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission File Number: 001-41411
Haleon plc
(Translationof registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Addressof principal executive offices)
Indicateby check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
ExhibitNumber | Description |
99.1 | 14August 2025 - “Transaction in Own Shares” |
99.1
Haleon plc: Transactionin own shares
14 August 2025: Haleonplc (the "Company" or "Haleon") today announces thepurchase of 830,000 ordinary shares of £0.01 each in theCompany (the "Shares") for cancellation underthe second tranche of its share buyback programme announced on 31July 2025.
| London Stock Exchange | CBOE (UK)/BXE | CBOE (UK)/CXE |
Date of purchase: | 13 August 2025 | 13 August 2025 | 13 August 2025 |
Number of Shares purchased: | 830,000 | - | - |
Highest price paid per Share (p): | 358.6000 | - | - |
Lowest price paid per Share (p): | 354.7000 | - | - |
Volume weighted average price paid per Share (p): | 356.7308 | - | - |
Following the settlement of the above, the Company's registeredshare capital is8,976,305,788 ordinary shares of £0.01 each, ofwhich 3,880,205 are held as treasury shares. Therefore,the number of ordinary shares with voting rights is 8,972,425,583and thisfigure may be used by shareholders to determine if they arerequired to notify their interest, or a change to their interest,in Haleon under the FCA's Disclosure Guidance and TransparencyRules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014as it applies in the UK (the Market Abuse Regulation), afull breakdown of the individual trades is available at the linkbelow:
http://www.rns-pdf.londonstockexchange.com/rns/2483V_1-2025-8-13.pdf
This announcement does not constitute, or form part of, an offer orany solicitation of an offer for securities in anyjurisdiction.
This announcement and individual trade breakdown will also beavailable on the Company's website at: www.haleon.com/investors.
Enquiries | |
Investors | Media |
Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
Rakesh Patel | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
Email: investor-relations@haleon.com | Email: corporate.media@haleon.com |
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, witha purpose to deliver better everyday health with humanity. Haleon'sproduct portfolio spans six major categories - Oral Health,Vitamins, Minerals and Supplements (VMS), Pain Relief, RespiratoryHealth, Digestive Health and Therapeutic Skin Health and Other. Itslong-standing brands - such as Advil, Centrum, Otrivin,Panadol, parodontax, Polident, Sensodyne,Theraflu and Voltaren - are built on trusted science, innovationand deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuantto the requirements of the Securities Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalfby the undersigned, thereunto duly authorized.
| | HALEON PLC (Registrant) |
Date:August 14, 2025 | By: | /s/Amanda Mellor |
| | Name: | AmandaMellor |
| | Title: | CompanySecretary |
